NO20082288L - Monoklonalt anti-ADDL-antistoff og anvendelse derav - Google Patents

Monoklonalt anti-ADDL-antistoff og anvendelse derav

Info

Publication number
NO20082288L
NO20082288L NO20082288A NO20082288A NO20082288L NO 20082288 L NO20082288 L NO 20082288L NO 20082288 A NO20082288 A NO 20082288A NO 20082288 A NO20082288 A NO 20082288A NO 20082288 L NO20082288 L NO 20082288L
Authority
NO
Norway
Prior art keywords
addl
types
antibodies
disease
monoclonal anti
Prior art date
Application number
NO20082288A
Other languages
English (en)
Norwegian (no)
Inventor
Zhiqiang An
William R Strohl
Gene Kinney
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20082288L publication Critical patent/NO20082288L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20082288A 2005-10-21 2008-05-19 Monoklonalt anti-ADDL-antistoff og anvendelse derav NO20082288L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2005381125 2005-10-21
PCT/US2006/040508 WO2007050359A2 (en) 2005-10-21 2006-10-17 Anti-addl monoclonal antibody and use thereof

Publications (1)

Publication Number Publication Date
NO20082288L true NO20082288L (no) 2008-05-19

Family

ID=39671607

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082288A NO20082288L (no) 2005-10-21 2008-05-19 Monoklonalt anti-ADDL-antistoff og anvendelse derav

Country Status (8)

Country Link
EP (1) EP1940466B1 (cg-RX-API-DMAC7.html)
JP (1) JP5289963B2 (cg-RX-API-DMAC7.html)
CN (1) CN101291692A (cg-RX-API-DMAC7.html)
AU (1) AU2006306553B9 (cg-RX-API-DMAC7.html)
CA (1) CA2626783A1 (cg-RX-API-DMAC7.html)
NO (1) NO20082288L (cg-RX-API-DMAC7.html)
RU (1) RU2008120027A (cg-RX-API-DMAC7.html)
WO (1) WO2007050359A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
HRP20150086T1 (xx) * 2007-06-12 2015-02-27 Ac Immune S.A. Humanizirana antitijela za beta amiloid
PL2238166T3 (pl) 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
EP2586797A3 (en) * 2007-11-27 2013-07-24 Medtronic, Inc. Humanized anti-amyloid beta antibodies
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
JP5529869B2 (ja) * 2008-08-14 2014-06-25 メルク・シャープ・アンド・ドーム・コーポレーション プロテインaアフィニティークロマトグラフィーを用いる抗体の精製方法
EP2510359B1 (en) 2009-12-11 2015-09-02 Araclón Biotech, S. L. Methods and reagents for improved detection of amyloid beta peptides
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9320793B2 (en) 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
US20130115227A1 (en) * 2010-07-14 2013-05-09 Renee C. Gaspar Anti-addl monoclonal antibody and uses thereof
US9176151B2 (en) 2010-07-14 2015-11-03 Acumen Pharmaceuticals, Inc. Antibodies, kit and method for detecting amyloid beta oligomers
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
CN103782171B (zh) * 2011-07-13 2016-12-14 默沙东公司 用于检测流体样品中淀粉状蛋白β寡聚体的方法及其用途
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
US10093731B2 (en) * 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0683234B2 (en) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
SI0994728T1 (sl) * 1997-04-09 2009-02-28 Intellect Neurosciences Inc Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo
JP2006508072A (ja) * 2002-10-01 2006-03-09 ノースウエスタン ユニバーシティ アミロイドベータ由来拡散性リガンド(ADDLs)、ADDL代替物、ADDL結合性分子、およびそれらの使用
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
KR20070094890A (ko) * 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 addl 항체 및 그 용도

Also Published As

Publication number Publication date
CA2626783A1 (en) 2007-05-03
AU2006306553B9 (en) 2011-09-29
JP2009519895A (ja) 2009-05-21
EP1940466A2 (en) 2008-07-09
EP1940466B1 (en) 2012-11-28
JP5289963B2 (ja) 2013-09-11
RU2008120027A (ru) 2009-11-27
AU2006306553A1 (en) 2007-05-03
WO2007050359A2 (en) 2007-05-03
WO2007050359A8 (en) 2008-05-08
CN101291692A (zh) 2008-10-22
EP1940466A4 (en) 2010-04-07
AU2006306553B2 (en) 2011-08-25
WO2007050359A3 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
NO20072700L (no) Anti-ADDL antistoffer og anvendelser derav
WO2007050359A3 (en) Anti-addl monoclonal antibody and use thereof
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
MX338640B (es) Anticuerpo monoclonal anti-ligando difundible derivado de amiloide beta y usos de los mismos.
WO2012045882A3 (en) Phosphospecific antibodies recognising tau
WO2010115843A3 (en) Pharmaceutical composition
MA45655A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
PH12021552334A1 (en) Antibodies to pyroglutamate amyloid-㟠and uses thereof
EA201100694A1 (ru) Антитело к cd38 человека и его применение
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2007062245A3 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
TR201800669T4 (tr) Alzheimer hastaliğinda tau-aracili patoloji̇ni̇n tanilanmasi ve protei̇n bazli tedavi̇si̇
AR083819A1 (es) UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
DE60336848D1 (de) Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
NO20076021L (no) Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
Bobkova et al. Immunization with either prion protein fragment 95–123 or the fragment-specific antibodies rescue memory loss and neurodegenerative phenotype of neurons in olfactory bulbectomized mice
WO2008051326A3 (en) Identification of contactins and l1- cams as ligands for the amyloid precursor protein
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application